These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26210951)

  • 1. Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.
    Li R; Chowdhury MY; Kim JH; Kim TH; Pathinayake P; Koo WS; Park ME; Yoon JE; Roh JB; Hong SP; Sung MH; Lee JS; Kim CJ
    Vet Microbiol; 2015 Sep; 179(3-4):250-63. PubMed ID: 26210951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
    Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
    Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.
    Chowdhury MY; Li R; Kim JH; Park ME; Kim TH; Pathinayake P; Weeratunga P; Song MK; Son HY; Hong SP; Sung MH; Lee JS; Kim CJ
    PLoS One; 2014; 9(4):e94051. PubMed ID: 24714362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programming of Influenza Vaccine Broadness and Persistence by Mucoadhesive Polymer-Based Adjuvant Systems.
    Noh HJ; Chowdhury MY; Cho S; Kim JH; Park HS; Kim CJ; Poo H; Sung MH; Lee JS; Lim YT
    J Immunol; 2015 Sep; 195(5):2472-82. PubMed ID: 26216889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of
    Lei H; Gao T; Cen Q
    Virulence; 2021 Dec; 12(1):12-19. PubMed ID: 33372841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection of Lactococcus lactis-displayed HA2 subunit against homologous and heterologous influenza A viruses in mice.
    Lei H; Peng X; Zhao D; Jiao H; Ouyang J
    Arch Virol; 2015 Dec; 160(12):3011-9. PubMed ID: 26358264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses of mice inoculated with recombinant Lactobacillus plantarum NC8 expressing the fusion gene HA2 and 3M2e of the influenza virus and protection against different subtypes of influenza virus.
    Bo F; Yang WT; Shonyela SM; Jin YB; Huang KY; Shao LN; Wang C; Zhou Y; Li QY; Jiang YL; Huang HB; Shi CW; Wang JZ; Wang G; Kang YH; Yang GL; Wang CF
    Virus Res; 2019 Apr; 263():64-72. PubMed ID: 30611823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal Administration of
    Huynh DT; Chathuranga WAG; Chathuranga K; Lee JS; Kim CJ
    J Microbiol Biotechnol; 2024 Mar; 34(3):735-745. PubMed ID: 37915251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.